Mitigating Severe Ribociclib-Hepatotoxicity With Corticosteroids
Ribociclib adds progression-free survival and overall survival benefit in combination with endocrine therapy for first-line treatment of advanced HR+ HER2− breast cancer; however, it comes with a risk of hepatotoxicity. There is guidance for monitoring liver function and holding the medication if he...
| Published in: | Case Reports in Oncological Medicine |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2026-01-01
|
| Online Access: | http://dx.doi.org/10.1155/crom/4222126 |